485 / DOI: 10.3332/ecancer.2014.485ecancer 8
Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project
Loading Article Metrics ... Please wait
18 Apr 2017 / DOI: 10.3332/ecancer.2017.734Published:
18 Apr 2017 / DOI: 10.3332/ecancer.2017.733Published:
04 Apr 2017 / DOI: 10.3332/ecancer.2017.731Published:
28 Mar 2017 / DOI: 10.3332/ecancer.2017.730Published: